Latest Conference Coverage

Promising Nasal Administration Treatment for Non-Active Secondary Progressive MS: Tarun Singhal, MD, MBBS

The director of the PET Imaging Program in Neurologic Diseases at Brigham and Women’s Hospital talked about nasal administration of foralumab that shows promise in treating patients with non-active secondary progressive MS. [WATCH TIME: 5 minutes]

NeuroVoices: Kayla Scippa, on Recognizing Unmet Need in Chronic Demyelinating Polyneuropathy

The associate director, Patient Reported Outcomes, Johnson & Johnson, provided clarity on a poster presentation from AAN 2024 examining the most critical aspects to CIDP disease severity.

Understanding the Impact of Data Analysis on Preventive Migraine Treatment: Jessica Ailani, MD

The director of the MedStar Georgetown Headache Center discussed the importance of maintaining hope and providing understanding of patients' frustrations in their treatment journey for migraine. [WATCH TIME: 5 minutes]

Understanding the Therapeutic Potential of Nipocalimab: Katie Abouzahr, MD

The vice president, Autoantibody Portfolio and Maternal Fetal Immunology Disease Area Leader, Johnson & Johnson, provided perspective on the unique molecular structure of nipocalimab seen across nonclinical and clinical studies. [WATCH TIME: 3 minutes]

A Call to Action to Address Disparities in Multiple Sclerosis Care: Jaime Imitola, MD

The chief of the Division of MS and Neuroimmunology at UConn Health talked about the challenges with access to care in multiple sclerosis, particularly for marginalized communities, despite significant progress made in the field over the past decades. [WATCH TIME: 4 minutes]

Addressing Potential Causes of Burnout Through Productive Solutions: Neil Busis, MD

The associate chair for technology and innovation at the NYU Grossman School of Medicine provided commentary on a study from AAN 2024 that examined the driving factors behind burnout in neurology departments. [WATCH TIME: 4 minutes]

Investigational Pump Agents to Treat Parkinson Disease

Understanding the Root Causes of Cognitive Decline in Disadvantaged Neighborhoods

Tanisha Hill-Jarrett, PhD, an assistant professor of neurology at the University of California, San Francisco Memory and Aging Center, discussed the change needed to improve cognitive decline rates in Black women in disadvantaged neighborhoods.

Emerging Novel Therapies in Development for PD

Ravulizumab’s Long-Term Efficacy and Safety as NMOSD Treatment: Sean Pittock, MD

The director for the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology provided an overview of the open-label extension of the phase 3 CHAMPION-NMOSD trial and how the newly approved ravulizumab fits with other NMOSD treatments. [WATCH TIME: 4 minutes]

Leveraging Artificial Intelligence to Redefine Clinical Efficacy and Empower Neurologists: Lidia Maria Veras Rocha Moura, MD, PhD, MPH, FAAN

The neurologist at Mass General Hospital talked about leveraging artificial intelligence to enhance clinical practice amidst growing demands and workforce shortages in neurology. [WATCH TIME: 4 minutes]

Latest Findings on AXS-05 Treatment for Agitation in Alzheimer Disease: Anton P. Porsteinsson, MD

The director of the Alzheimer's Disease Care, Research and Education Program at the University of Rochester talked about recent results on the phase 3 ACCORD trial assessing AXS-05 for agitation in Alzheimer disease. [WATCH TIME: 8 minutes]

Utilizing the SCACOMS Composite Measure to Assess Treatment Benefit of Troriluzole in Spinocerebellar Ataxia: Irfan Qureshi, MD

The chief medical officer at Biohaven provided insight on its investigational spinocerebellar ataxia agent troriluzole, the advantages of the newly developed SCACOMS measure, and how the therapy stacks against natural history data. [WATCH TIME: 4 minutes]

Literature Review Demonstrates Ravulizumab’s Superior Efficacy Over Other Approved NMOSD Treatments

In comparison to previously approved treatments like satralizumab and inebilizumab, ravulizumab-treated patients performed significant better on outcomes of first relapse and time to first relapse.

Complement Inhibitors Ravulizumab and Eculizumab Impact Measures of Neuroaxonal Damage

Ravulizumab reduced NfL levels in cerebrospinal fluid and serum whereas eculizumab showed no change in NfL when compared with placebo.

Potential of Nasal Foralumab in Treating Non-Active Secondary Progressive MS: Tarun Singhal, MD, MBBS

The associate professor of neurology at Harvard Medical School discussed findings from a study investigating nasal foralumab in patients with non-active secondary progressive multiple sclerosis. [WATCH TIME: 5 minutes]

Understanding the Cognitive Impact of Neighborhood Disadvantage on Black Women: Tanisha Hill-Jarrett, PhD

The neuropsychologist and assistant professor of neurology at the University of California, San Francisco Memory and Aging Center provided comment on her presentation from AAN 2024 examining the association of area deprivation index with cognitive functioning in Black women. [WATCH TIME: 3 minutes]

Use of Antiemetics in Parkinson Care

Optimizing Dosing and Treatment Selection of Amantadine

Insights on Addressing Disparities in Alzheimer Disease Research: Renã A. S. Robinson, PhD

The full professor of chemistry at Vanderbilt University talked about research surrounding racial and ethnic disparities in Alzheimer disease incidence. [WATCH TIME: 5 minutes]

Therapeutic Potential of Transcranial Direct Current Stimulation in Primary Progressive Aphasia: Leigh Charvet, PhD

The professor of neurology at the NYU Grossman School of Medicine provided commentary on a study that demonstrated the benefits of using tDCS along with sleep language training to promote naming in primary progressive aphasia. [WATCH TIME: 5 minutes]

Examining Promising Phase 2b PARADIGM Findings of ALS Agent PrimeC: Merit Cudkowicz, MD, MSc

The chair of neurology at Massachusetts General Hospital talked about results from the phase 2b PARADIGM trial assessing PrimeC, an ALS combination agent that consists of ciprofloxacin and celecoxib. [WATCH TIME: 4 minutes]

Investigational Agent EDG-5506 Shows Promising 2-Year Data in Becker Muscular Dystrophy

After 2 years of treatment, EDG-5506, otherwise known as sevasemten, was well-tolerated, with rapid and sustained decreases in biomarkers of muscle damage.

Understanding the Clinical Utility of Low-Contrast Letter Acuity and RAN Tasks in Alzheimer Disease

Lauren Seidman, a second-year medical student at NYU Langone’s Grossman School of Medicine, provided perspective on a poster at AAN 2024 highlighting the use of binocular visual function testing in Alzheimer disease.

Safety Considerations for Ravulizumab in NMOSD From Open-Label Extension Data: Sean Pittock, MD

The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology discussed the safety of ravulizumab and the ways to avoid risks of meningococcal infection. [WATCH TIME: 3 minutes]

Nasal Foralumab Shows Attenuation of Microglial Activation, Clinical Stabilization in Non-Active Secondary Progressive MS With PIRA

Foralumab's anti-CD3 mechanism modulates T cell function, offering potential benefits for the challenging-to-treat na-SPMS patients.

Consistent Efficacy of Eptinezumab as Migraine Prevention Treatment: Jessica Ailani, MD

The director of the MedStar Georgetown Headache Center talked about an intravenous migraine treatment that could offer long-term relief for most patients who respond well to the initial dose. [WATCH TIME: 5 minutes]

Ofatumumab Demonstrates Sustained Efficacy in Recently Diagnosed and Treatment-Naive Relapsing Multiple Sclerosis Over 6 Years

Ofatumumab showed a consistent and long-term reduction in relapse rates and MRI lesion activity in patients with recently diagnosed, treatment-naïve relapsing multiple sclerosis.

The Potential of Embolization as a Treatment Approach for Subdural Hematomas: Jason M. Davies, MD, PhD

The assistant professor of neurosurgery and biomedical informatics at the State University of New York at Buffalo talked about the efficacy and safety of using embolization as a promising treatment for subdural hematomas. [WATCH TIME: 3 minutes]

Parkinson Gene Therapy AB-1005 Continues to Show Promising Results at 18 Months

Patients experienced improvements in ON/OFF time and motor function, with favorable tolerability, paving the way for a phase 2 trial.